Optimal pharmacotherapy for transplant ineligible multiple myeloma
CADTH
Record ID 32018002252
English
Authors' objectives:
Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada.
Publicly funded drug plans requested this therapeutic review to determine what sequences drugs for transplant-ineligible multiple myeloma should be reimbursed to maximize clinical and cost-effectiveness while considering patient safety,
characteristics, experience, and preferences.
Details
Project Status:
Completed
URL for protocol:
https://www.cadth.ca/sites/default/files/ou-tr/TR0014-multiple-myeloma-protocol-final.pdf
Year Published:
2024
URL for published report:
https://www.cda-amc.ca/sites/default/files/DRR/2024/TR0014%20Final%20Recommendation%20and%20Reasons.pdf
URL for additional information:
https://cadth.ca/optimal-pharmacotherapy-transplant-ineligible-multiple-myeloma
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
MeSH Terms
- Multiple Myeloma
- Drug Therapy
- Antibodies, Monoclonal
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
Keywords
- Multiple myeloma
- Drug therapy
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.